Analyzing the Global Generics Industry 2017
In recent times there has been a growing focus on the generic drugs industry worldwide. The patent expiry of leading drugs in recent years and also the upcoming patent expiries has put a focus on the global generics industry. Over the years, the global generic drugs industry has grown strongly owing partly to the fact that the period for patent protection has gotten shorter with major blockbuster drugs losing their patent protection.
Furthermore, governments around the world have put in place many policies that are encouraging the growth of generic usage and regulations have also established pricing systems to promote the development of the generic drugs sector.
Aruvian Research analyzes the global generics industry in its research report Analyzing the Global Generics Industry 2017. This in-depth analysis of the global generics industry includes an industry definition, historical development of the industry, industry statistics, value and volume analysis, industry segmentation by geography, amongst others. We analyze the issue of patent expiries by therapeutic areas in details, looking at what the impact is on the generic drugs market. We also look at the industry structure, market entry as well as research & development in the industry. A Porter's Five Forces Strategy analysis of the global generics industry is also included in the report. Data analyzed in this in-depth research report is for the years 2012 to 2021.
The impact of regulatory framework on the generics industry in Europe, Japan and the United States is analyzed in the report, along with the trends and challenges in the global generics industry. We also look at the popularity of small molecule generic drugs as well as the growing focus on biosimilars. Challenge of life cycle management strategies are also looked at. Global generics industry strategies are analyzed as well.
An analysis of major markets is carried out through industry overview, industry value & volume analysis, industry segmentation by geography and an industry forecast. Key markets analyzed include Brazil, Canada, China, France, Germany, India, Italy, Japan, the Netherlands, South Africa, South Korea, Spain, the UK and the United States.
An important aspect of the global generics market is the pricing and reimbursement of generic drugs in major markets. We analyze the pricing and reimbursement in the key markets of Australia, Austria, China, Czech Republic, France, Germany, Hungary, India, Italy, Japan, Norway, Poland, Romania, Spain, Sweden, the UK and the United States.
An industry forecast of the global generics industry is included till 2021 through a value and volume forecast.
Major players in the industry are analyzed through a corporate profile, analysis of business segments, major products and services, therapeutic snapshot, financial analysis and a SWOT analysis as well. Major players analyzed in this report include Allergan, Daiichi Sankyo, Lupin, Mylan Inc, Sanofi, STADA Arzneimittel AG, TEVA Pharmaceutical Industries, Apotex, and many others.
Furthermore, governments around the world have put in place many policies that are encouraging the growth of generic usage and regulations have also established pricing systems to promote the development of the generic drugs sector.
Aruvian Research analyzes the global generics industry in its research report Analyzing the Global Generics Industry 2017. This in-depth analysis of the global generics industry includes an industry definition, historical development of the industry, industry statistics, value and volume analysis, industry segmentation by geography, amongst others. We analyze the issue of patent expiries by therapeutic areas in details, looking at what the impact is on the generic drugs market. We also look at the industry structure, market entry as well as research & development in the industry. A Porter's Five Forces Strategy analysis of the global generics industry is also included in the report. Data analyzed in this in-depth research report is for the years 2012 to 2021.
The impact of regulatory framework on the generics industry in Europe, Japan and the United States is analyzed in the report, along with the trends and challenges in the global generics industry. We also look at the popularity of small molecule generic drugs as well as the growing focus on biosimilars. Challenge of life cycle management strategies are also looked at. Global generics industry strategies are analyzed as well.
An analysis of major markets is carried out through industry overview, industry value & volume analysis, industry segmentation by geography and an industry forecast. Key markets analyzed include Brazil, Canada, China, France, Germany, India, Italy, Japan, the Netherlands, South Africa, South Korea, Spain, the UK and the United States.
An important aspect of the global generics market is the pricing and reimbursement of generic drugs in major markets. We analyze the pricing and reimbursement in the key markets of Australia, Austria, China, Czech Republic, France, Germany, Hungary, India, Italy, Japan, Norway, Poland, Romania, Spain, Sweden, the UK and the United States.
An industry forecast of the global generics industry is included till 2021 through a value and volume forecast.
Major players in the industry are analyzed through a corporate profile, analysis of business segments, major products and services, therapeutic snapshot, financial analysis and a SWOT analysis as well. Major players analyzed in this report include Allergan, Daiichi Sankyo, Lupin, Mylan Inc, Sanofi, STADA Arzneimittel AG, TEVA Pharmaceutical Industries, Apotex, and many others.
A. EXECUTIVE SUMMARY
B. ANALYZING THE GLOBAL GENERICS INDUSTRY
B.1 Industry Definition
B.2 Historical Development of the Industry
B.3 Industry Overview
B.4 Industry Value & Volume Analysis
B.5 Industry Segmentation by Geography
B.6 Patent Expiries
B.7 Patent Expiries by Therapeutic Areas
B.8 Global Generic Industry Structure
B.9 Market Entry
B.10 Research & Development in the Industry
C. GLOBAL GENERICS INDUSTRY: PORTER’S FIVE FORCES STRATEGY ANALYSIS
C.1 Introduction
C.2 Bargaining Power of Buyers
C.3 Bargaining Power of Suppliers
C.4 Competitive Rivalry in the Industry
C.5 Threat of New Entrants
C.6 Threat of Substitutes
D. REGULATORY FRAMEWORK & IMPACT ON THE GENERICS INDUSTRY
D.1 Europe
D.2 Japan
D.3 United States
E. INDUSTRY TRENDS & CHALLENGES
E.1 ‘Pro-Generics’ Legislation on the Rise
E.2 Popularity of Small Molecule Generic Drugs
E.3 Growing Focus on Biosimilars
E.4 Potential in Various Untapped Generics Markets
E.5 Multiple Patent Protections on Drugs
E.6 Challenge of Life Cycle Management Strategy of Pharma Innovators
E.7 Low Research & Development Productivity
F. INDUSTRY STRATEGIES
F.1 Rise in Mergers & Acquisitions
F.2 Effectively Using Outsourcing
F.3 Hatch-Waxman Act and Paragraph IV Certifications
F.4 Emergence of Authorized Generics/Copies
F.5 Popularity of Strategic Alliances
F.6 Presence in Emerging Markets
G. GLOBAL GENERICS INDUSTRY: ANALYSIS OF MAJOR MARKETS
G.1 Australia
G.1.1 Industry Overview
G.1.2 Industry Value & Volume
G.1.3 Industry Segmentation by Geography
G.1.4 Industry Forecast
G.2 Brazil
G.2.1 Industry Overview
G.2.2 Industry Value & Volume
G.2.3 Industry Segmentation by Geography
G.2.4 Industry Forecast
G.3 Canada
G.3.1 Industry Overview
G.3.2 Industry Value & Volume
G.3.3 Industry Segmentation by Geography
G.3.4 Industry Forecast
G.4 China
G.4.1 Industry Overview
G.4.2 Industry Value & Volume
G.4.3 Industry Segmentation by Geography
G.4.4 Industry Forecast
G.5 France
G.5.1 Industry Overview
G.5.2 Industry Value & Volume
G.5.3 Industry Segmentation by Geography
G.5.4 Industry Forecast
G.6 Germany
G.6.1 Industry Overview
G.6.2 Industry Value & Volume
G.6.3 Industry Segmentation by Geography
G.6.4 Industry Forecast
G.7 India
G.7.1 Industry Overview
G.7.2 Industry Value & Volume
G.7.3 Industry Segmentation by Geography
G.7.4 Industry Forecast
G.8 Indonesia
G.8.1 Industry Overview
G.8.2 Industry Value & Volume
G.8.3 Industry Segmentation by Geography
G.8.4 Industry Forecast
G.9 Italy
G.9.1 Industry Overview
G.9.2 Industry Value & Volume
G.9.3 Industry Segmentation by Geography
G.9.4 Industry Forecast
G.10 Japan
G.10.1 Industry Overview
G.10.2 Industry Value & Volume
G.10.3 Industry Segmentation by Geography
G.10.4 Industry Forecast
G.11 Mexico
G.11.1 Industry Overview
G.11.2 Industry Value & Volume
G.11.3 Industry Segmentation by Geography
G.11.4 Industry Forecast
G.12 Netherlands
G.12.1 Industry Overview
G.12.2 Industry Value & Volume
G.12.3 Industry Segmentation by Geography
G.12.4 Industry Forecast
G.13 Singapore
G.13.1 Industry Overview
G.13.2 Industry Value & Volume
G.13.3 Industry Segmentation by Geography
G.13.4 Industry Forecast
G.14 South Africa
G.14.1 Industry Overview
G.14.2 Industry Value & Volume
G.14.3 Industry Segmentation by Geography
G.14.4 Industry Forecast
G.15 South Korea
G.15.1 Industry Overview
G.15.2 Industry Value & Volume
G.15.3 Industry Segmentation by Geography
G.15.4 Industry Forecast
G.16 Spain
G.16.1 Industry Overview
G.16.2 Industry Value & Volume
G.16.3 Industry Segmentation by Geography
G.16.4 Industry Forecast
G.17 United Kingdom
G.17.1 Industry Overview
G.17.2 Industry Value & Volume
G.17.3 Industry Segmentation by Geography
G.17.4 Industry Forecast
G.18 United States
G.18.1 Industry Overview
G.18.2 Industry Value & Volume
G.18.3 Industry Segmentation by Geography
G.18.4 Industry Forecast
H. PRICING AND REIMBURSEMENT OF GENERICS: AN ANALYSIS BY MAJOR MARKETS
H.1 Overview
H.2 Pricing & Reimbursement in Australia
H.2.1 Overview
H.2.2 Generics Pricing & Reimbursement Scenario
H.2.3 Trends & Challenges
H.3 Pricing & Reimbursement in Austria
H.3.1 Overview
H.3.2 Generics Pricing & Reimbursement Scenario
H.3.3 Trends & Challenges
H.4 Pricing & Reimbursement in China
H.4.1 Overview
H.4.2 Generics Pricing & Reimbursement Scenario
H.4.3 Trends & Challenges
H.5 Pricing & Reimbursement in the Czech Republic
H.5.1 Overview
H.5.2 Generics Pricing & Reimbursement Scenario
H.5.3 Trends & Challenges
H.6 Pricing & Reimbursement in France
H.6.1 Overview
H.6.2 Generics Pricing & Reimbursement Scenario
H.6.3 Trends & Challenges
H.7 Pricing & Reimbursement in Germany
H.7.1 Overview
H.7.2 Generics Pricing & Reimbursement Scenario
H.7.3 Trends & Challenges
H.8 Pricing & Reimbursement in Hungary
H.8.1 Overview
H.8.2 Generics Pricing & Reimbursement Scenario
H.8.3 Trends & Challenges
H.9 Pricing & Reimbursement in India
H.9.1 Overview
H.9.2 Generics Pricing & Reimbursement Scenario
H.9.3 Trends & Challenges
H.10 Pricing & Reimbursement in Italy
H.10.1 Overview
H.10.2 Generics Pricing & Reimbursement Scenario
H.10.3 Trends & Challenges
H.11 Pricing & Reimbursement in Japan
H.11.1 Overview
H.11.2 Generics Pricing & Reimbursement Scenario
H.11.3 Trends & Challenges
H.12 Pricing & Reimbursement in Norway
H.12.1 Overview
H.12.2 Generics Pricing & Reimbursement Scenario
H.12.3 Trends & Challenges
H.13 Pricing & Reimbursement in Poland
H.13.1 Overview
H.13.2 Generics Pricing & Reimbursement Scenario
H.13.3 Trends & Challenges
H.14 Pricing & Reimbursement in Romania
H.14.1 Overview
H.14.2 Generics Pricing & Reimbursement Scenario
H.14.3 Trends & Challenges
H.15 Pricing & Reimbursement in Spain
H.15.1 Overview
H.15.2 Generics Pricing & Reimbursement Scenario
H.15.3 Trends & Challenges
H.16 Pricing & Reimbursement in United Kingdom
H.16.1 Overview
H.16.2 Generics Pricing & Reimbursement Scenario
H.16.3 Trends & Challenges
H.17 Pricing & Reimbursement in United States
H.17.1 Overview
H.17.2 Regulation
H.17.3 Health Insurance
H.17.4 Generics Pricing
H.17.5 Reimbursement Scenario
H.17.6 Trends & Case Studies
H.17.7 Challenges
I. GLOBAL GENERICS INDUSTRY FORECAST
J. MAJOR INDUSTRY PLAYERS
J.1 Allergan Plc
J.1.1 Corporate Analysis
J.1.2 Financial Analysis
J.1.3 SWOT Analysis
J.2 Apotex Inc.
J.2.1 Corporate Analysis
J.2.2 Financial Analysis
J.2.3 SWOT Analysis
J.3 Aspen Pharmacare Holdings Ltd
J.3.1 Corporate Analysis
J.3.2 Financial Analysis
J.3.3 SWOT Analysis
J.4 Cipla Limited
J.4.1 Corporate Analysis
J.4.2 Financial Analysis
J.4.3 SWOT Analysis
J.5 Daiichi Sankyo Co., Ltd.
J.5.1 Corporate Analysis
J.5.2 Financial Analysis
J.5.3 SWOT Analysis
J.6 Les Laboratoires Servier
J.6.1 Corporate Analysis
J.6.2 Financial Analysis
J.6.3 SWOT Analysis
J.7 Lupin Limited
J.7.1 Corporate Analysis
J.7.2 Financial Analysis
J.7.3 SWOT Analysis
J.8 Mylan N.V.
J.8.1 Corporate Analysis
J.8.2 Financial Analysis
J.8.3 SWOT Analysis
J.9 PT Kalbe Farma Tbk
J.9.1 Corporate Analysis
J.9.2 Financial Analysis
J.9.3 SWOT Analysis
J.10 Sanofi SA
J.10.1 Corporate Analysis
J.10.2 Financial Analysis
J.10.3 SWOT Analysis
J.11 STADA Arzneimittel AG
J.11.1 Corporate Analysis
J.11.2 Financial Analysis
J.11.3 SWOT Analysis
J.12 Teva Pharmaceutical Industries Limited
J.12.1 Corporate Analysis
J.12.2 Financial Analysis
J.12.3 SWOT Analysis
J.13 Yuhan Corporation
J.13.1 Corporate Analysis
J.13.2 Financial Analysis
J.13.3 SWOT Analysis
J.14 Adcock Ingram Holdings Limited
J.15 Aurobindo Pharma Limited
J.16 China Grand Pharmaceutical and Healthcare Holdings Limited
J.17 EMS Sigma Pharma
J.18 Esteve Group
J.19 Eurofarma Laborat?rios Ltda
J.20 O Ach? Laborat?rios Farmac?uticos SA
J.21 PT Indofarma (Persero), Tbk
J.22 PT Sanbe Farma
J.23 PT Soho Global Health
J.24 Sandoz International GmbH
J.25 Sawai Pharmaceutical Company Ltd
J.26 Sun Pharmaceutical Industries Ltd.
K. GLOSSARY OF TERMS
B. ANALYZING THE GLOBAL GENERICS INDUSTRY
B.1 Industry Definition
B.2 Historical Development of the Industry
B.3 Industry Overview
B.4 Industry Value & Volume Analysis
B.5 Industry Segmentation by Geography
B.6 Patent Expiries
B.7 Patent Expiries by Therapeutic Areas
B.8 Global Generic Industry Structure
B.9 Market Entry
B.10 Research & Development in the Industry
C. GLOBAL GENERICS INDUSTRY: PORTER’S FIVE FORCES STRATEGY ANALYSIS
C.1 Introduction
C.2 Bargaining Power of Buyers
C.3 Bargaining Power of Suppliers
C.4 Competitive Rivalry in the Industry
C.5 Threat of New Entrants
C.6 Threat of Substitutes
D. REGULATORY FRAMEWORK & IMPACT ON THE GENERICS INDUSTRY
D.1 Europe
D.2 Japan
D.3 United States
E. INDUSTRY TRENDS & CHALLENGES
E.1 ‘Pro-Generics’ Legislation on the Rise
E.2 Popularity of Small Molecule Generic Drugs
E.3 Growing Focus on Biosimilars
E.4 Potential in Various Untapped Generics Markets
E.5 Multiple Patent Protections on Drugs
E.6 Challenge of Life Cycle Management Strategy of Pharma Innovators
E.7 Low Research & Development Productivity
F. INDUSTRY STRATEGIES
F.1 Rise in Mergers & Acquisitions
F.2 Effectively Using Outsourcing
F.3 Hatch-Waxman Act and Paragraph IV Certifications
F.4 Emergence of Authorized Generics/Copies
F.5 Popularity of Strategic Alliances
F.6 Presence in Emerging Markets
G. GLOBAL GENERICS INDUSTRY: ANALYSIS OF MAJOR MARKETS
G.1 Australia
G.1.1 Industry Overview
G.1.2 Industry Value & Volume
G.1.3 Industry Segmentation by Geography
G.1.4 Industry Forecast
G.2 Brazil
G.2.1 Industry Overview
G.2.2 Industry Value & Volume
G.2.3 Industry Segmentation by Geography
G.2.4 Industry Forecast
G.3 Canada
G.3.1 Industry Overview
G.3.2 Industry Value & Volume
G.3.3 Industry Segmentation by Geography
G.3.4 Industry Forecast
G.4 China
G.4.1 Industry Overview
G.4.2 Industry Value & Volume
G.4.3 Industry Segmentation by Geography
G.4.4 Industry Forecast
G.5 France
G.5.1 Industry Overview
G.5.2 Industry Value & Volume
G.5.3 Industry Segmentation by Geography
G.5.4 Industry Forecast
G.6 Germany
G.6.1 Industry Overview
G.6.2 Industry Value & Volume
G.6.3 Industry Segmentation by Geography
G.6.4 Industry Forecast
G.7 India
G.7.1 Industry Overview
G.7.2 Industry Value & Volume
G.7.3 Industry Segmentation by Geography
G.7.4 Industry Forecast
G.8 Indonesia
G.8.1 Industry Overview
G.8.2 Industry Value & Volume
G.8.3 Industry Segmentation by Geography
G.8.4 Industry Forecast
G.9 Italy
G.9.1 Industry Overview
G.9.2 Industry Value & Volume
G.9.3 Industry Segmentation by Geography
G.9.4 Industry Forecast
G.10 Japan
G.10.1 Industry Overview
G.10.2 Industry Value & Volume
G.10.3 Industry Segmentation by Geography
G.10.4 Industry Forecast
G.11 Mexico
G.11.1 Industry Overview
G.11.2 Industry Value & Volume
G.11.3 Industry Segmentation by Geography
G.11.4 Industry Forecast
G.12 Netherlands
G.12.1 Industry Overview
G.12.2 Industry Value & Volume
G.12.3 Industry Segmentation by Geography
G.12.4 Industry Forecast
G.13 Singapore
G.13.1 Industry Overview
G.13.2 Industry Value & Volume
G.13.3 Industry Segmentation by Geography
G.13.4 Industry Forecast
G.14 South Africa
G.14.1 Industry Overview
G.14.2 Industry Value & Volume
G.14.3 Industry Segmentation by Geography
G.14.4 Industry Forecast
G.15 South Korea
G.15.1 Industry Overview
G.15.2 Industry Value & Volume
G.15.3 Industry Segmentation by Geography
G.15.4 Industry Forecast
G.16 Spain
G.16.1 Industry Overview
G.16.2 Industry Value & Volume
G.16.3 Industry Segmentation by Geography
G.16.4 Industry Forecast
G.17 United Kingdom
G.17.1 Industry Overview
G.17.2 Industry Value & Volume
G.17.3 Industry Segmentation by Geography
G.17.4 Industry Forecast
G.18 United States
G.18.1 Industry Overview
G.18.2 Industry Value & Volume
G.18.3 Industry Segmentation by Geography
G.18.4 Industry Forecast
H. PRICING AND REIMBURSEMENT OF GENERICS: AN ANALYSIS BY MAJOR MARKETS
H.1 Overview
H.2 Pricing & Reimbursement in Australia
H.2.1 Overview
H.2.2 Generics Pricing & Reimbursement Scenario
H.2.3 Trends & Challenges
H.3 Pricing & Reimbursement in Austria
H.3.1 Overview
H.3.2 Generics Pricing & Reimbursement Scenario
H.3.3 Trends & Challenges
H.4 Pricing & Reimbursement in China
H.4.1 Overview
H.4.2 Generics Pricing & Reimbursement Scenario
H.4.3 Trends & Challenges
H.5 Pricing & Reimbursement in the Czech Republic
H.5.1 Overview
H.5.2 Generics Pricing & Reimbursement Scenario
H.5.3 Trends & Challenges
H.6 Pricing & Reimbursement in France
H.6.1 Overview
H.6.2 Generics Pricing & Reimbursement Scenario
H.6.3 Trends & Challenges
H.7 Pricing & Reimbursement in Germany
H.7.1 Overview
H.7.2 Generics Pricing & Reimbursement Scenario
H.7.3 Trends & Challenges
H.8 Pricing & Reimbursement in Hungary
H.8.1 Overview
H.8.2 Generics Pricing & Reimbursement Scenario
H.8.3 Trends & Challenges
H.9 Pricing & Reimbursement in India
H.9.1 Overview
H.9.2 Generics Pricing & Reimbursement Scenario
H.9.3 Trends & Challenges
H.10 Pricing & Reimbursement in Italy
H.10.1 Overview
H.10.2 Generics Pricing & Reimbursement Scenario
H.10.3 Trends & Challenges
H.11 Pricing & Reimbursement in Japan
H.11.1 Overview
H.11.2 Generics Pricing & Reimbursement Scenario
H.11.3 Trends & Challenges
H.12 Pricing & Reimbursement in Norway
H.12.1 Overview
H.12.2 Generics Pricing & Reimbursement Scenario
H.12.3 Trends & Challenges
H.13 Pricing & Reimbursement in Poland
H.13.1 Overview
H.13.2 Generics Pricing & Reimbursement Scenario
H.13.3 Trends & Challenges
H.14 Pricing & Reimbursement in Romania
H.14.1 Overview
H.14.2 Generics Pricing & Reimbursement Scenario
H.14.3 Trends & Challenges
H.15 Pricing & Reimbursement in Spain
H.15.1 Overview
H.15.2 Generics Pricing & Reimbursement Scenario
H.15.3 Trends & Challenges
H.16 Pricing & Reimbursement in United Kingdom
H.16.1 Overview
H.16.2 Generics Pricing & Reimbursement Scenario
H.16.3 Trends & Challenges
H.17 Pricing & Reimbursement in United States
H.17.1 Overview
H.17.2 Regulation
H.17.3 Health Insurance
H.17.4 Generics Pricing
H.17.5 Reimbursement Scenario
H.17.6 Trends & Case Studies
H.17.7 Challenges
I. GLOBAL GENERICS INDUSTRY FORECAST
J. MAJOR INDUSTRY PLAYERS
J.1 Allergan Plc
J.1.1 Corporate Analysis
J.1.2 Financial Analysis
J.1.3 SWOT Analysis
J.2 Apotex Inc.
J.2.1 Corporate Analysis
J.2.2 Financial Analysis
J.2.3 SWOT Analysis
J.3 Aspen Pharmacare Holdings Ltd
J.3.1 Corporate Analysis
J.3.2 Financial Analysis
J.3.3 SWOT Analysis
J.4 Cipla Limited
J.4.1 Corporate Analysis
J.4.2 Financial Analysis
J.4.3 SWOT Analysis
J.5 Daiichi Sankyo Co., Ltd.
J.5.1 Corporate Analysis
J.5.2 Financial Analysis
J.5.3 SWOT Analysis
J.6 Les Laboratoires Servier
J.6.1 Corporate Analysis
J.6.2 Financial Analysis
J.6.3 SWOT Analysis
J.7 Lupin Limited
J.7.1 Corporate Analysis
J.7.2 Financial Analysis
J.7.3 SWOT Analysis
J.8 Mylan N.V.
J.8.1 Corporate Analysis
J.8.2 Financial Analysis
J.8.3 SWOT Analysis
J.9 PT Kalbe Farma Tbk
J.9.1 Corporate Analysis
J.9.2 Financial Analysis
J.9.3 SWOT Analysis
J.10 Sanofi SA
J.10.1 Corporate Analysis
J.10.2 Financial Analysis
J.10.3 SWOT Analysis
J.11 STADA Arzneimittel AG
J.11.1 Corporate Analysis
J.11.2 Financial Analysis
J.11.3 SWOT Analysis
J.12 Teva Pharmaceutical Industries Limited
J.12.1 Corporate Analysis
J.12.2 Financial Analysis
J.12.3 SWOT Analysis
J.13 Yuhan Corporation
J.13.1 Corporate Analysis
J.13.2 Financial Analysis
J.13.3 SWOT Analysis
J.14 Adcock Ingram Holdings Limited
J.15 Aurobindo Pharma Limited
J.16 China Grand Pharmaceutical and Healthcare Holdings Limited
J.17 EMS Sigma Pharma
J.18 Esteve Group
J.19 Eurofarma Laborat?rios Ltda
J.20 O Ach? Laborat?rios Farmac?uticos SA
J.21 PT Indofarma (Persero), Tbk
J.22 PT Sanbe Farma
J.23 PT Soho Global Health
J.24 Sandoz International GmbH
J.25 Sawai Pharmaceutical Company Ltd
J.26 Sun Pharmaceutical Industries Ltd.
K. GLOSSARY OF TERMS
LIST OF FIGURES
Figure 1: Review Process of a Generic Drug
Figure 2: Patent Certification Types by ANDA & US FDA Approval Processes
Figure 3: Historical Revenues of Leading Generic Companies (in USD Million), 2008-2009
Figure 4: Growth of the Global Generics Industry by Value (in USD Billion), 2012-2016
Figure 5: Generics Percentage of Total Pharmaceutical Volume & Market Volume of Global Generics Industry (%), 2012-2016
Figure 6: Global Generics Market Segmentation by Geography (%), 2016
Figure 7: Revenues of Top 10 Drugs that went off Patent between 2010-2014 (in USD Million)
Figure 8: Value of Drugs to Lose Patent Protection during 2010-2014 by Therapeutic Area (%)
Figure 9: Market Share of Leading Generic Companies Worldwide (%), 2016
Figure 10: Comparison of Revenues of Leading Generic Companies (in USD Million), 2013-2014
Figure 11: Porter's Five Forces Analysis of the Global Generic Industry
Figure 12: Bargaining Power of Buyers in the Global Generic Industry
Figure 13: Bargaining Power of Suppliers in the Global Generic Industry
Figure 14: Competitive Rivalry in the Global Generic Industry
Figure 15: Threat of New Entrants in the Global Generic Industry
Figure 16: Threat of Substitutes in the Global Generic Industry
Figure 17: Impact of Regulation on the Generics Market in the US
Figure 18: ANDA Filings, 2004-2012
Figure 19: ANDA Approvals, 2007-2012
Figure 20: Market Share of Generics in Selected Countries for Off-Patent Drugs Sector
Figure 21: Number of LCM Projects in Late-stage Development by Therapeutic Area, 2016
Figure 22: R&D Expenditure and Sales of Leading Pharma Companies (%), 2011-2016
Figure 23: Acquisitions by Matrix Labs
Figure 24: Region-wise Contribution to Growth of Leading Generic Companies, 2011-2016
Figure 25: Healthcare Financing by Selected Countries, 2016
Figure 26: Value of the Generics Market in Australia (in USD Billion), 2012-2016
Figure 27: Volume Growth of the Generics Market in Australia (%), 2012-2016
Figure 28: Share of Australia in the Asia Pacific Generics Industry (%), 2016
Figure 29: Forecast of the Generics Market in Australia (in USD Billion), 2016-2021
Figure 30: Volume Forecast of the Generics Market in Australia (%), 2016-2021
Figure 31: Value of the Generics Market in Brazil (in USD Billion), 2012-2016
Figure 32: Volume Growth of the Generics Market in Brazil (%), 2012-2016
Figure 33: Share of Brazil in the Americas Generics Industry (%), 2016
Figure 34: Forecast of the Generics Market in Brazil (in USD Billion), 2016-2021
Figure 35: Volume Forecast of the Generics Market in Brazil (%), 2016-2021
Figure 36: Value of the Generics Market in Canada (in USD Billion), 2012-2016
Figure 37: Volume Growth of the Generics Market in Canada (%), 2012-2016
Figure 38: Share of Canada in the Americas Generics Industry (%), 2016
Figure 39: Forecast of the Generics Market in Canada (in USD Billion), 2016-2021
Figure 40: Volume Forecast of the Generics Market in Canada (%), 2016-2021
Figure 41: Value of the Generics Market in China (in USD Billion), 2012-2016
Figure 42: Volume Growth of the Generics Market in China (%), 2012-2016
Figure 43: Share of China in the Asia Pacific Generics Industry (%), 2016
Figure 44: Forecast of the Generics Market in China (in USD Billion), 2016-2021
Figure 45: Volume Forecast of the Generics Market in China (%), 2016-2021
Figure 46: Value of the Generics Market in France (in USD Billion), 2012-2016
Figure 47: Volume Growth of the Generics Market in France (%), 2012-2016
Figure 48: Share of France in the European Generics Industry (%), 2016
Figure 49: Forecast of the Generics Market in France (in USD Billion), 2016-2021
Figure 50: Volume Forecast of the Generics Market in France (%), 2016-2021
Figure 51: Value of the Generics Market in Germany (in USD Billion), 2012-2016
Figure 52: Volume Growth of the Generics Market in Germany (%), 2012-2016
Figure 53: Share of Germany in the European Generics Industry (%), 2016
Figure 54: Forecast of the Generics Market in Germany (in USD Billion), 2016-2021
Figure 55: Volume Forecast of the Generics Market in Germany (%), 2016-2021
Figure 56: Value of the Generics Market in India (in USD Billion), 2012-2016
Figure 57: Volume Growth of the Generics Market in India (%), 2012-2016
Figure 58: Share of India in the Asia Pacific Generics Industry (%), 2016
Figure 59: Forecast of the Generics Market in India (in USD Billion), 2016-2021
Figure 60: Volume Forecast of the Generics Market in India (%), 2016-2021
Figure 61: Value of the Generics Market in Indonesia (in USD Billion), 2012-2016
Figure 62: Volume Growth of the Generics Market in Indonesia (%), 2012-2016
Figure 63: Share of Indonesia in the Asia Pacific Generics Industry (%), 2016
Figure 64: Forecast of the Generics Market in Indonesia (in USD Billion), 2016-2021
Figure 65: Volume Forecast of the Generics Market in Indonesia (%), 2016-2021
Figure 66: Value of the Generics Market in Italy (in USD Billion), 2012-2016
Figure 67: Volume Growth of the Generics Market in Italy (%), 2012-2016
Figure 68: Share of Italy in the European Generics Industry (%), 2016
Figure 69: Forecast of the Generics Market in Italy (in USD Billion), 2016-2021
Figure 70: Volume Forecast of the Generics Market in Italy (%), 2016-2021
Figure 71: Value of the Generics Market in Japan (in USD Billion), 2012-2016
Figure 72: Volume Growth of the Generics Market in Japan (%), 2012-2016
Figure 73: Share of Japan in the Asia Pacific Generics Industry (%), 2016
Figure 74: Forecast of the Generics Market in Japan (in USD Billion), 2016-2021
Figure 75: Volume Forecast of the Generics Market in Japan (%), 2016-2021
Figure 76: Value of the Generics Market in Mexico (in USD Billion), 2012-2016
Figure 77: Volume Growth of the Generics Market in Mexico (%), 2012-2016
Figure 78: Share of Mexico in the Americas Generics Industry (%), 2016
Figure 79: Forecast of the Generics Market in Mexico (in USD Billion), 2016-2021
Figure 80: Volume Forecast of the Generics Market in Mexico (%), 2016-2021
Figure 81: Value of the Generics Market in the Netherlands (in USD Billion), 2012-2016
Figure 82: Volume Growth of the Generics Market in the Netherlands (%), 2012-2016
Figure 83: Share of Netherlands in the European Generics Industry (%), 2016
Figure 84: Forecast of the Generics Market in the Netherlands (in USD Billion), 2016-2021
Figure 85: Volume Forecast of the Generics Market in the Netherlands (%), 2016-2021
Figure 86: Value of the Generics Market in Singapore (in USD Billion), 2012-2016
Figure 87 : Volume Growth of the Generics Market in Singapore (%), 2012-2016
Figure 88: Share of Singapore in the Asia Pacific Generics Industry (%), 2016
Figure 89: Forecast of the Generics Market in Singapore (in USD Billion), 2016-2021
Figure 90: Volume Forecast of the Generics Market in Singapore (%), 2016-2021
Figure 91: Value of the Generics Market in South Africa (in USD Billion), 2012-2016
Figure 92: Volume Growth of the Generics Market in South Africa (%), 2012-2016
Figure 93: Share of South Africa in the MEA Generics Industry (%), 2016
Figure 94: Forecast of the Generics Market in South Africa (in USD Billion), 2016-2021
Figure 95: Volume Forecast of the Generics Market in South Africa (%), 2016-2021
Figure 96: Value of the Generics Market in South Korea (in USD Billion), 2012-2016
Figure 97: Volume Growth of the Generics Market in South Korea (%), 2012-2016
Figure 98: Share of South Korea in the Asia Pacific Generics Industry (%), 2016
Figure 99: Forecast of the Generics Market in South Korea (in USD Billion), 2016-2021
Figure 100: Volume Forecast of the Generics Market in South Korea (%), 2016-2021
Figure 101: Value of the Generics Market in Spain (in USD Billion), 2012-2016
Figure 102: Volume Growth of the Generics Market in Spain (%), 2012-2016
Figure 103: Share of Spain in the European Generics Industry (%), 2016
Figure 104: Forecast of the Generics Market in Spain (in USD Billion), 2016-2021
Figure 105: Volume Forecast of the Generics Market in Spain (%), 2016-2021
Figure 106: Value of the Generics Market in the UK (in USD Billion), 2012-2016
Figure 107: Volume Growth of the Generics Market in the UK (%), 2012-2016
Figure 108: Share of the UK in the European Generics Industry (%), 2016
Figure 109: Forecast of the Generics Market in the UK (in USD Billion), 2016-2021
Figure 110: Volume Forecast of the Generics Market in the UK (%), 2016-2021
Figure 111: Value of the Generics Market in the US (in USD Billion), 2012-2016
Figure 112: Volume Growth of the Generics Market in the US (%), 2012-2016
Figure 113: Share of the US in the Global Generics Industry (%), 2016
Figure 114: Forecast of the Generics Market in the US (in USD Billion), 2016-2021
Figure 115: Volume Forecast of the Generics Market in the US (%), 2016-2021
Figure 116: Healthcare Regulatory Agencies in China & their Responsibilities
Figure 117: Financing Law of Social Security (Loi de Financement de la S?curit? Sociale) in France
Figure 118: Impacts on Drug Prices in India
Figure 119: Stepped Price System in Norway
Figure 120: Distribution Channel and Logistics of Generics in the US
Figure 121: Fee for Service, Preferred Provider Organization & Health Maintenance Organization in the US
Figure 122: Standard Medicare Part D Benefit Comparison of 2011 & 2020 in the US
Figure 123: Global Generics Industry Forecast (in USD Billion), 2016-2021
Figure 124: Global Generics Industry Forecast by Volume (% of Pharma Volume), 2016-2021
Figure 125: Revenues & Profitability of Allergan Plc (in USD Million), 2011-2015
Figure 126: Revenues & Profitability of Aspen Pharmacare (in USD Million), 2011-2015
Figure 127: Revenues & Profitability of Cipla Limited (in USD Million), 2011-2015
Figure 128: Revenues & Profitability of Daiichi Sankyo (in USD Million), 2011-2015
Figure 129: Revenues & Profitability of Lupin (in USD Million), 2011-2015
Figure 130: Revenues & Profitability of PT Kalbe Farma Tbk (in USD Million), 2011-2015
Figure 131: Revenues & Profitability of Sanofi SA (in USD Million), 2011-2015
Figure 132: Revenues & Profitability of STADA Arzneimittel AG (in USD Million), 2011-2015
Figure 133: Revenues & Profitability of Teva Pharmaceutical (in USD Million), 2011-2015
Figure 134: Revenues & Profitability of Yuhan Corporation (in USD Million), 2011-2015
Figure 135: Revenues & Profitability of Adcock Ingram (in USD Million), 2011-2015
Figure 136: Revenues & Profitability of Aurobindo Pharma (in USD Million), 2011-2015
Figure 137: Revenues & Profitability of China Grand Pharmaceutical and Healthcare (in USD Million), 2011-2015
Figure 138: Revenues & Profitability of PT Indofarma (Persero) (in USD Million), 2011-2015
Figure 139: Revenues & Profitability of Sawai Pharmaceutical (in USD Million), 2011-2015
Figure 140: Revenues & Profitability of Sun Pharmaceutical (in USD Million), 2011-2015
Figure 1: Review Process of a Generic Drug
Figure 2: Patent Certification Types by ANDA & US FDA Approval Processes
Figure 3: Historical Revenues of Leading Generic Companies (in USD Million), 2008-2009
Figure 4: Growth of the Global Generics Industry by Value (in USD Billion), 2012-2016
Figure 5: Generics Percentage of Total Pharmaceutical Volume & Market Volume of Global Generics Industry (%), 2012-2016
Figure 6: Global Generics Market Segmentation by Geography (%), 2016
Figure 7: Revenues of Top 10 Drugs that went off Patent between 2010-2014 (in USD Million)
Figure 8: Value of Drugs to Lose Patent Protection during 2010-2014 by Therapeutic Area (%)
Figure 9: Market Share of Leading Generic Companies Worldwide (%), 2016
Figure 10: Comparison of Revenues of Leading Generic Companies (in USD Million), 2013-2014
Figure 11: Porter's Five Forces Analysis of the Global Generic Industry
Figure 12: Bargaining Power of Buyers in the Global Generic Industry
Figure 13: Bargaining Power of Suppliers in the Global Generic Industry
Figure 14: Competitive Rivalry in the Global Generic Industry
Figure 15: Threat of New Entrants in the Global Generic Industry
Figure 16: Threat of Substitutes in the Global Generic Industry
Figure 17: Impact of Regulation on the Generics Market in the US
Figure 18: ANDA Filings, 2004-2012
Figure 19: ANDA Approvals, 2007-2012
Figure 20: Market Share of Generics in Selected Countries for Off-Patent Drugs Sector
Figure 21: Number of LCM Projects in Late-stage Development by Therapeutic Area, 2016
Figure 22: R&D Expenditure and Sales of Leading Pharma Companies (%), 2011-2016
Figure 23: Acquisitions by Matrix Labs
Figure 24: Region-wise Contribution to Growth of Leading Generic Companies, 2011-2016
Figure 25: Healthcare Financing by Selected Countries, 2016
Figure 26: Value of the Generics Market in Australia (in USD Billion), 2012-2016
Figure 27: Volume Growth of the Generics Market in Australia (%), 2012-2016
Figure 28: Share of Australia in the Asia Pacific Generics Industry (%), 2016
Figure 29: Forecast of the Generics Market in Australia (in USD Billion), 2016-2021
Figure 30: Volume Forecast of the Generics Market in Australia (%), 2016-2021
Figure 31: Value of the Generics Market in Brazil (in USD Billion), 2012-2016
Figure 32: Volume Growth of the Generics Market in Brazil (%), 2012-2016
Figure 33: Share of Brazil in the Americas Generics Industry (%), 2016
Figure 34: Forecast of the Generics Market in Brazil (in USD Billion), 2016-2021
Figure 35: Volume Forecast of the Generics Market in Brazil (%), 2016-2021
Figure 36: Value of the Generics Market in Canada (in USD Billion), 2012-2016
Figure 37: Volume Growth of the Generics Market in Canada (%), 2012-2016
Figure 38: Share of Canada in the Americas Generics Industry (%), 2016
Figure 39: Forecast of the Generics Market in Canada (in USD Billion), 2016-2021
Figure 40: Volume Forecast of the Generics Market in Canada (%), 2016-2021
Figure 41: Value of the Generics Market in China (in USD Billion), 2012-2016
Figure 42: Volume Growth of the Generics Market in China (%), 2012-2016
Figure 43: Share of China in the Asia Pacific Generics Industry (%), 2016
Figure 44: Forecast of the Generics Market in China (in USD Billion), 2016-2021
Figure 45: Volume Forecast of the Generics Market in China (%), 2016-2021
Figure 46: Value of the Generics Market in France (in USD Billion), 2012-2016
Figure 47: Volume Growth of the Generics Market in France (%), 2012-2016
Figure 48: Share of France in the European Generics Industry (%), 2016
Figure 49: Forecast of the Generics Market in France (in USD Billion), 2016-2021
Figure 50: Volume Forecast of the Generics Market in France (%), 2016-2021
Figure 51: Value of the Generics Market in Germany (in USD Billion), 2012-2016
Figure 52: Volume Growth of the Generics Market in Germany (%), 2012-2016
Figure 53: Share of Germany in the European Generics Industry (%), 2016
Figure 54: Forecast of the Generics Market in Germany (in USD Billion), 2016-2021
Figure 55: Volume Forecast of the Generics Market in Germany (%), 2016-2021
Figure 56: Value of the Generics Market in India (in USD Billion), 2012-2016
Figure 57: Volume Growth of the Generics Market in India (%), 2012-2016
Figure 58: Share of India in the Asia Pacific Generics Industry (%), 2016
Figure 59: Forecast of the Generics Market in India (in USD Billion), 2016-2021
Figure 60: Volume Forecast of the Generics Market in India (%), 2016-2021
Figure 61: Value of the Generics Market in Indonesia (in USD Billion), 2012-2016
Figure 62: Volume Growth of the Generics Market in Indonesia (%), 2012-2016
Figure 63: Share of Indonesia in the Asia Pacific Generics Industry (%), 2016
Figure 64: Forecast of the Generics Market in Indonesia (in USD Billion), 2016-2021
Figure 65: Volume Forecast of the Generics Market in Indonesia (%), 2016-2021
Figure 66: Value of the Generics Market in Italy (in USD Billion), 2012-2016
Figure 67: Volume Growth of the Generics Market in Italy (%), 2012-2016
Figure 68: Share of Italy in the European Generics Industry (%), 2016
Figure 69: Forecast of the Generics Market in Italy (in USD Billion), 2016-2021
Figure 70: Volume Forecast of the Generics Market in Italy (%), 2016-2021
Figure 71: Value of the Generics Market in Japan (in USD Billion), 2012-2016
Figure 72: Volume Growth of the Generics Market in Japan (%), 2012-2016
Figure 73: Share of Japan in the Asia Pacific Generics Industry (%), 2016
Figure 74: Forecast of the Generics Market in Japan (in USD Billion), 2016-2021
Figure 75: Volume Forecast of the Generics Market in Japan (%), 2016-2021
Figure 76: Value of the Generics Market in Mexico (in USD Billion), 2012-2016
Figure 77: Volume Growth of the Generics Market in Mexico (%), 2012-2016
Figure 78: Share of Mexico in the Americas Generics Industry (%), 2016
Figure 79: Forecast of the Generics Market in Mexico (in USD Billion), 2016-2021
Figure 80: Volume Forecast of the Generics Market in Mexico (%), 2016-2021
Figure 81: Value of the Generics Market in the Netherlands (in USD Billion), 2012-2016
Figure 82: Volume Growth of the Generics Market in the Netherlands (%), 2012-2016
Figure 83: Share of Netherlands in the European Generics Industry (%), 2016
Figure 84: Forecast of the Generics Market in the Netherlands (in USD Billion), 2016-2021
Figure 85: Volume Forecast of the Generics Market in the Netherlands (%), 2016-2021
Figure 86: Value of the Generics Market in Singapore (in USD Billion), 2012-2016
Figure 87 : Volume Growth of the Generics Market in Singapore (%), 2012-2016
Figure 88: Share of Singapore in the Asia Pacific Generics Industry (%), 2016
Figure 89: Forecast of the Generics Market in Singapore (in USD Billion), 2016-2021
Figure 90: Volume Forecast of the Generics Market in Singapore (%), 2016-2021
Figure 91: Value of the Generics Market in South Africa (in USD Billion), 2012-2016
Figure 92: Volume Growth of the Generics Market in South Africa (%), 2012-2016
Figure 93: Share of South Africa in the MEA Generics Industry (%), 2016
Figure 94: Forecast of the Generics Market in South Africa (in USD Billion), 2016-2021
Figure 95: Volume Forecast of the Generics Market in South Africa (%), 2016-2021
Figure 96: Value of the Generics Market in South Korea (in USD Billion), 2012-2016
Figure 97: Volume Growth of the Generics Market in South Korea (%), 2012-2016
Figure 98: Share of South Korea in the Asia Pacific Generics Industry (%), 2016
Figure 99: Forecast of the Generics Market in South Korea (in USD Billion), 2016-2021
Figure 100: Volume Forecast of the Generics Market in South Korea (%), 2016-2021
Figure 101: Value of the Generics Market in Spain (in USD Billion), 2012-2016
Figure 102: Volume Growth of the Generics Market in Spain (%), 2012-2016
Figure 103: Share of Spain in the European Generics Industry (%), 2016
Figure 104: Forecast of the Generics Market in Spain (in USD Billion), 2016-2021
Figure 105: Volume Forecast of the Generics Market in Spain (%), 2016-2021
Figure 106: Value of the Generics Market in the UK (in USD Billion), 2012-2016
Figure 107: Volume Growth of the Generics Market in the UK (%), 2012-2016
Figure 108: Share of the UK in the European Generics Industry (%), 2016
Figure 109: Forecast of the Generics Market in the UK (in USD Billion), 2016-2021
Figure 110: Volume Forecast of the Generics Market in the UK (%), 2016-2021
Figure 111: Value of the Generics Market in the US (in USD Billion), 2012-2016
Figure 112: Volume Growth of the Generics Market in the US (%), 2012-2016
Figure 113: Share of the US in the Global Generics Industry (%), 2016
Figure 114: Forecast of the Generics Market in the US (in USD Billion), 2016-2021
Figure 115: Volume Forecast of the Generics Market in the US (%), 2016-2021
Figure 116: Healthcare Regulatory Agencies in China & their Responsibilities
Figure 117: Financing Law of Social Security (Loi de Financement de la S?curit? Sociale) in France
Figure 118: Impacts on Drug Prices in India
Figure 119: Stepped Price System in Norway
Figure 120: Distribution Channel and Logistics of Generics in the US
Figure 121: Fee for Service, Preferred Provider Organization & Health Maintenance Organization in the US
Figure 122: Standard Medicare Part D Benefit Comparison of 2011 & 2020 in the US
Figure 123: Global Generics Industry Forecast (in USD Billion), 2016-2021
Figure 124: Global Generics Industry Forecast by Volume (% of Pharma Volume), 2016-2021
Figure 125: Revenues & Profitability of Allergan Plc (in USD Million), 2011-2015
Figure 126: Revenues & Profitability of Aspen Pharmacare (in USD Million), 2011-2015
Figure 127: Revenues & Profitability of Cipla Limited (in USD Million), 2011-2015
Figure 128: Revenues & Profitability of Daiichi Sankyo (in USD Million), 2011-2015
Figure 129: Revenues & Profitability of Lupin (in USD Million), 2011-2015
Figure 130: Revenues & Profitability of PT Kalbe Farma Tbk (in USD Million), 2011-2015
Figure 131: Revenues & Profitability of Sanofi SA (in USD Million), 2011-2015
Figure 132: Revenues & Profitability of STADA Arzneimittel AG (in USD Million), 2011-2015
Figure 133: Revenues & Profitability of Teva Pharmaceutical (in USD Million), 2011-2015
Figure 134: Revenues & Profitability of Yuhan Corporation (in USD Million), 2011-2015
Figure 135: Revenues & Profitability of Adcock Ingram (in USD Million), 2011-2015
Figure 136: Revenues & Profitability of Aurobindo Pharma (in USD Million), 2011-2015
Figure 137: Revenues & Profitability of China Grand Pharmaceutical and Healthcare (in USD Million), 2011-2015
Figure 138: Revenues & Profitability of PT Indofarma (Persero) (in USD Million), 2011-2015
Figure 139: Revenues & Profitability of Sawai Pharmaceutical (in USD Million), 2011-2015
Figure 140: Revenues & Profitability of Sun Pharmaceutical (in USD Million), 2011-2015
LIST OF TABLES
Table 1: Growth of the Global Generics Industry by Value (in USD Billion), 2012-2016
Table 2: Generics Percentage of Total Pharmaceutical Volume & Market Volume of Global Generics Industry (%), 2012-2016
Table 3: Global Generics Industry, Segmentation by Geography (in USD Billion), 2016
Table 4: Major Patent Expiries
Table 5: Patent Expiries for Leading Biologic Drugs, 2010-2016
Table 6: Regulations for Usage of Generic Drugs in Selected EU Countries
Table 7: Incentives for Generic Drugs in Selected EU Countries
Table 8: Companies Moving towards Vertical Integration
Table 9: Major Authorized Generics, as of February 17, 2017
Table 10: Value of the Generics Market in Australia (in USD Billion), 2012-2016
Table 11: Volume Growth of the Generics Market in Australia (%), 2012-2016
Table 12: Share of Australia in the Asia Pacific Generics Industry (in USD Billion & %), 2016
Table 13: Forecast of the Generics Market in Australia (in USD Billion), 2016-2021
Table 14: Volume Forecast of the Generics Market in Australia (%), 2016-2021
Table 15: Value of the Generics Market in Brazil (in USD Billion), 2012-2016
Table 16: Volume Growth of the Generics Market in Brazil (%), 2012-2016
Table 17: Share of Brazil in the Americas Generics Industry (in USD Billion & %), 2016
Table 18: Forecast of the Generics Market in Brazil (in USD Billion), 2016-2021
Table 19: Volume Forecast of the Generics Market in Brazil (%), 2016-2021
Table 20: Value of the Generics Market in Canada (in USD Billion), 2012-2016
Table 21: Volume Growth of the Generics Market in Canada (%), 2012-2016
Table 22: Share of Canada in the Americas Generics Industry (% & USD Billion), 2016
Table 23: Forecast of the Generics Market in Canada (in USD Billion), 2016-2021
Table 24: Volume Forecast of the Generics Market in Canada (%), 2016-2021
Table 25: Value of the Generics Market in China (in USD Billion), 2012-2016
Table 26: Volume Growth of the Generics Market in China (%), 2012-2016
Table 27: Share of China in the Asia Pacific Generics Industry (% & USD Billion), 2016
Table 28: Forecast of the Generics Market in China (in USD Billion), 2016-2021
Table 29: Volume Forecast of the Generics Market in China (%), 2016-2021
Table 30: Value of the Generics Market in France (in USD Billion), 2012-2016
Table 31: Volume Growth of the Generics Market in France (%), 2012-2016
Table 32: Share of France in the European Generics Industry (% & USD Billion), 2016
Table 33: Forecast of the Generics Market in France (in USD Billion), 2016-2021
Table 34: Volume Forecast of the Generics Market in France (%), 2016-2021
Table 35: Value of the Generics Market in Germany (in USD Billion), 2012-2016
Table 36: Volume Growth of the Generics Market in Germany (%), 2012-2016
Table 37: Share of Germany in the European Generics Industry (% & USD Billion), 2016
Table 38: Forecast of the Generics Market in Germany (in USD Billion), 2016-2021
Table 39: Volume Forecast of the Generics Market in Germany (%), 2016-2021
Table 40: Value of the Generics Market in India (in USD Billion), 2012-2016
Table 41: Volume Growth of the Generics Market in India (%), 2012-2016
Table 42: Share of India in the Asia Pacific Generics Industry (in USD Billion & %), 2016
Table 43: Forecast of the Generics Market in India (in USD Billion), 2016-2021
Table 44: Volume Forecast of the Generics Market in India (%), 2016-2021
Table 45: Value of the Generics Market in Indonesia (in USD Billion), 2012-2016
Table 46: Volume Growth of the Generics Market in Indonesia (%), 2012-2016
Table 47: Share of Indonesia in the Asia Pacific Generics Industry (in USD Billion & %), 2016
Table 48: Forecast of the Generics Market in Indonesia (in USD Billion), 2016-2021
Table 49: Volume Forecast of the Generics Market in Indonesia (%), 2016-2021
Table 50: Value of the Generics Market in Italy (in USD Billion), 2012-2016
Table 51: Volume Growth of the Generics Market in Italy (%), 2012-2016
Table 52: Share of Italy in the European Generics Industry (% & USD Billion), 2016
Table 53: Forecast of the Generics Market in Italy (in USD Billion), 2016-2021
Table 54: Volume Forecast of the Generics Market in Italy (%), 2016-2021
Table 55: Value of the Generics Market in Japan (in USD Billion), 2012-2016
Table 56: Volume Growth of the Generics Market in Japan (%), 2012-2016
Table 57: Share of Japan in the Asia Pacific Generics Industry (% & USD Billion), 2016
Table 58: Forecast of the Generics Market in Japan (in USD Billion), 2016-2021
Table 59: Volume Forecast of the Generics Market in Japan (%), 2016-2021
Table 60: Value of the Generics Market in Mexico (in USD Billion), 2012-2016
Table 61: Volume Growth of the Generics Market in Mexico (%), 2012-2016
Table 62: Share of Mexico in the Americas Generics Industry (in USD Billion & %), 2016
Table 63: Forecast of the Generics Market in Mexico (in USD Billion), 2016-2021
Table 64: Volume Forecast of the Generics Market in Mexico (%), 2016-2021
Table 65: Value of the Generics Market in the Netherlands (in USD Billion), 2012-2016
Table 66: Volume Growth of the Generics Market in the Netherlands (%), 2012-2016
Table 67: Share of Netherlands in the European Generics Industry (% & USD Billion), 2016
Table 68: Forecast of the Generics Market in the Netherlands (in USD Billion), 2016-2021
Table 69: Volume Forecast of the Generics Market in the Netherlands (%), 2016-2021
Table 70: Value of the Generics Market in Singapore (in USD Billion), 2012-2016
Table 71: Volume Growth of the Generics Market in Singapore (%), 2012-2016
Table 72: Share of Singapore in the Asia Pacific Generics Industry (in USD Billion & %), 2016
Table 73: Forecast of the Generics Market in Singapore (in USD Billion), 2016-2021
Table 74: Volume Forecast of the Generics Market in Singapore (%), 2016-2021
Table 75: Value of the Generics Market in South Africa (in USD Billion), 2012-2016
Table 76: Volume Growth of the Generics Market in South Africa (%), 2012-2016
Table 77: Share of South Africa in the MEA Generics Industry (in USD Billion & %), 2016
Table 78: Forecast of the Generics Market in South Africa (in USD Billion), 2016-2021
Table 79: Volume Forecast of the Generics Market in South Africa (%), 2016-2021
Table 80: Value of the Generics Market in South Korea (in USD Billion), 2012-2016
Table 81: Volume Growth of the Generics Market in South Korea (%), 2012-2016
Table 82: Share of South Korea in the Asia Pacific Generics Industry (in USD Billion & %), 2016
Table 83: Forecast of the Generics Market in South Korea (in USD Billion), 2016-2021
Table 84: Volume Forecast of the Generics Market in South Korea (%), 2016-2021
Table 85: Value of the Generics Market in Spain (in USD Billion), 2012-2016
Table 86: Volume Growth of the Generics Market in Spain (%), 2012-2016
Table 87: Share of Spain in the European Generics Industry (% & USD Billion), 2016
Table 88: Forecast of the Generics Market in Spain (in USD Billion), 2016-2021
Table 89: Volume Forecast of the Generics Market in Spain (%), 2016-2021
Table 90: Value of the Generics Market in the UK (in USD Billion), 2012-2016
Table 91: Volume Growth of the Generics Market in the UK (%), 2012-2016
Table 92: Share of the UK in the European Generics Industry (% & USD Billion), 2016
Table 93: Forecast of the Generics Market in the UK (in USD Billion), 2016-2021
Table 94: Volume Forecast of the Generics Market in the UK (%), 2016-2021
Table 95: Value of the Generics Market in the US (in USD Billion), 2012-2016
Table 96: Volume Growth of the Generics Market in the US (%), 2012-2016
Table 97: Share of the US in the Global Generics Industry (% & USD Billion), 2016
Table 98: Forecast of the Generics Market in the US (in USD Billion), 2016-2021
Table 99: Volume Forecast of the Generics Market in the US (%), 2016-2021
Table 100: Austria's Box Model for Reimbursement
Table 101: Drug Prices in Jan Aushadhi Shops in India Compared to Market Prices
Table 102: Reimbursement Categories of Medicines in Norway
Table 103: Average Retail Coinsurance Rates by Tier, (%)
Table 104: Global Generics Industry Forecast (in USD Billion), 2016-2021
Table 105: Global Generics Industry Forecast by Volume & Percentage Growth (% of Pharma Volume), 2016-2021
Table 106: Key Financials of Allergan Plc (in USD Million), 2011-2015
Table 107: Key Financials of Aspen Pharmacare (in USD Million), 2011-2015
Table 108: Key Financials of Cipla Limited (in USD Million), 2011-2015
Table 109: Key Financials of Daiichi Sankyo (in USD Million), 2011-2015
Table 110: Key Financials of Lupin (in USD Million), 2011-2015
Table 111: Key Financials of PT Kalbe Farma Tbk (in USD Million), 2011-2015
Table 112: Key Financials of Sanofi SA (in USD Million), 2011-2015
Table 113: Key Financials of STADA Arzneimittel AG (in USD Million), 2011-2015
Table 114: Key Financials of Teva Pharmaceutical (in USD Million), 2011-2015
Table 115: Key Financials of Yuhan Corporation (in USD Million), 2011-2015
Table 116: Key Financials of Adcock Ingram (in USD Million), 2011-2015
Table 117: Key Financials of Aurobindo Pharma (in USD Million), 2011-2015
Table 118: Key Financials of China Grand Pharmaceutical and Healthcare (in USD Million), 2011-2015
Table 119: Key Financials of PT Indofarma (Persero) (in USD Million), 2011-2015
Table 120: Key Financials of Sawai Pharmaceutical (in USD Million), 2011-2015
Table 121: Key Financials of Sun Pharmaceutical (in USD Million), 2011-2015
Table 1: Growth of the Global Generics Industry by Value (in USD Billion), 2012-2016
Table 2: Generics Percentage of Total Pharmaceutical Volume & Market Volume of Global Generics Industry (%), 2012-2016
Table 3: Global Generics Industry, Segmentation by Geography (in USD Billion), 2016
Table 4: Major Patent Expiries
Table 5: Patent Expiries for Leading Biologic Drugs, 2010-2016
Table 6: Regulations for Usage of Generic Drugs in Selected EU Countries
Table 7: Incentives for Generic Drugs in Selected EU Countries
Table 8: Companies Moving towards Vertical Integration
Table 9: Major Authorized Generics, as of February 17, 2017
Table 10: Value of the Generics Market in Australia (in USD Billion), 2012-2016
Table 11: Volume Growth of the Generics Market in Australia (%), 2012-2016
Table 12: Share of Australia in the Asia Pacific Generics Industry (in USD Billion & %), 2016
Table 13: Forecast of the Generics Market in Australia (in USD Billion), 2016-2021
Table 14: Volume Forecast of the Generics Market in Australia (%), 2016-2021
Table 15: Value of the Generics Market in Brazil (in USD Billion), 2012-2016
Table 16: Volume Growth of the Generics Market in Brazil (%), 2012-2016
Table 17: Share of Brazil in the Americas Generics Industry (in USD Billion & %), 2016
Table 18: Forecast of the Generics Market in Brazil (in USD Billion), 2016-2021
Table 19: Volume Forecast of the Generics Market in Brazil (%), 2016-2021
Table 20: Value of the Generics Market in Canada (in USD Billion), 2012-2016
Table 21: Volume Growth of the Generics Market in Canada (%), 2012-2016
Table 22: Share of Canada in the Americas Generics Industry (% & USD Billion), 2016
Table 23: Forecast of the Generics Market in Canada (in USD Billion), 2016-2021
Table 24: Volume Forecast of the Generics Market in Canada (%), 2016-2021
Table 25: Value of the Generics Market in China (in USD Billion), 2012-2016
Table 26: Volume Growth of the Generics Market in China (%), 2012-2016
Table 27: Share of China in the Asia Pacific Generics Industry (% & USD Billion), 2016
Table 28: Forecast of the Generics Market in China (in USD Billion), 2016-2021
Table 29: Volume Forecast of the Generics Market in China (%), 2016-2021
Table 30: Value of the Generics Market in France (in USD Billion), 2012-2016
Table 31: Volume Growth of the Generics Market in France (%), 2012-2016
Table 32: Share of France in the European Generics Industry (% & USD Billion), 2016
Table 33: Forecast of the Generics Market in France (in USD Billion), 2016-2021
Table 34: Volume Forecast of the Generics Market in France (%), 2016-2021
Table 35: Value of the Generics Market in Germany (in USD Billion), 2012-2016
Table 36: Volume Growth of the Generics Market in Germany (%), 2012-2016
Table 37: Share of Germany in the European Generics Industry (% & USD Billion), 2016
Table 38: Forecast of the Generics Market in Germany (in USD Billion), 2016-2021
Table 39: Volume Forecast of the Generics Market in Germany (%), 2016-2021
Table 40: Value of the Generics Market in India (in USD Billion), 2012-2016
Table 41: Volume Growth of the Generics Market in India (%), 2012-2016
Table 42: Share of India in the Asia Pacific Generics Industry (in USD Billion & %), 2016
Table 43: Forecast of the Generics Market in India (in USD Billion), 2016-2021
Table 44: Volume Forecast of the Generics Market in India (%), 2016-2021
Table 45: Value of the Generics Market in Indonesia (in USD Billion), 2012-2016
Table 46: Volume Growth of the Generics Market in Indonesia (%), 2012-2016
Table 47: Share of Indonesia in the Asia Pacific Generics Industry (in USD Billion & %), 2016
Table 48: Forecast of the Generics Market in Indonesia (in USD Billion), 2016-2021
Table 49: Volume Forecast of the Generics Market in Indonesia (%), 2016-2021
Table 50: Value of the Generics Market in Italy (in USD Billion), 2012-2016
Table 51: Volume Growth of the Generics Market in Italy (%), 2012-2016
Table 52: Share of Italy in the European Generics Industry (% & USD Billion), 2016
Table 53: Forecast of the Generics Market in Italy (in USD Billion), 2016-2021
Table 54: Volume Forecast of the Generics Market in Italy (%), 2016-2021
Table 55: Value of the Generics Market in Japan (in USD Billion), 2012-2016
Table 56: Volume Growth of the Generics Market in Japan (%), 2012-2016
Table 57: Share of Japan in the Asia Pacific Generics Industry (% & USD Billion), 2016
Table 58: Forecast of the Generics Market in Japan (in USD Billion), 2016-2021
Table 59: Volume Forecast of the Generics Market in Japan (%), 2016-2021
Table 60: Value of the Generics Market in Mexico (in USD Billion), 2012-2016
Table 61: Volume Growth of the Generics Market in Mexico (%), 2012-2016
Table 62: Share of Mexico in the Americas Generics Industry (in USD Billion & %), 2016
Table 63: Forecast of the Generics Market in Mexico (in USD Billion), 2016-2021
Table 64: Volume Forecast of the Generics Market in Mexico (%), 2016-2021
Table 65: Value of the Generics Market in the Netherlands (in USD Billion), 2012-2016
Table 66: Volume Growth of the Generics Market in the Netherlands (%), 2012-2016
Table 67: Share of Netherlands in the European Generics Industry (% & USD Billion), 2016
Table 68: Forecast of the Generics Market in the Netherlands (in USD Billion), 2016-2021
Table 69: Volume Forecast of the Generics Market in the Netherlands (%), 2016-2021
Table 70: Value of the Generics Market in Singapore (in USD Billion), 2012-2016
Table 71: Volume Growth of the Generics Market in Singapore (%), 2012-2016
Table 72: Share of Singapore in the Asia Pacific Generics Industry (in USD Billion & %), 2016
Table 73: Forecast of the Generics Market in Singapore (in USD Billion), 2016-2021
Table 74: Volume Forecast of the Generics Market in Singapore (%), 2016-2021
Table 75: Value of the Generics Market in South Africa (in USD Billion), 2012-2016
Table 76: Volume Growth of the Generics Market in South Africa (%), 2012-2016
Table 77: Share of South Africa in the MEA Generics Industry (in USD Billion & %), 2016
Table 78: Forecast of the Generics Market in South Africa (in USD Billion), 2016-2021
Table 79: Volume Forecast of the Generics Market in South Africa (%), 2016-2021
Table 80: Value of the Generics Market in South Korea (in USD Billion), 2012-2016
Table 81: Volume Growth of the Generics Market in South Korea (%), 2012-2016
Table 82: Share of South Korea in the Asia Pacific Generics Industry (in USD Billion & %), 2016
Table 83: Forecast of the Generics Market in South Korea (in USD Billion), 2016-2021
Table 84: Volume Forecast of the Generics Market in South Korea (%), 2016-2021
Table 85: Value of the Generics Market in Spain (in USD Billion), 2012-2016
Table 86: Volume Growth of the Generics Market in Spain (%), 2012-2016
Table 87: Share of Spain in the European Generics Industry (% & USD Billion), 2016
Table 88: Forecast of the Generics Market in Spain (in USD Billion), 2016-2021
Table 89: Volume Forecast of the Generics Market in Spain (%), 2016-2021
Table 90: Value of the Generics Market in the UK (in USD Billion), 2012-2016
Table 91: Volume Growth of the Generics Market in the UK (%), 2012-2016
Table 92: Share of the UK in the European Generics Industry (% & USD Billion), 2016
Table 93: Forecast of the Generics Market in the UK (in USD Billion), 2016-2021
Table 94: Volume Forecast of the Generics Market in the UK (%), 2016-2021
Table 95: Value of the Generics Market in the US (in USD Billion), 2012-2016
Table 96: Volume Growth of the Generics Market in the US (%), 2012-2016
Table 97: Share of the US in the Global Generics Industry (% & USD Billion), 2016
Table 98: Forecast of the Generics Market in the US (in USD Billion), 2016-2021
Table 99: Volume Forecast of the Generics Market in the US (%), 2016-2021
Table 100: Austria's Box Model for Reimbursement
Table 101: Drug Prices in Jan Aushadhi Shops in India Compared to Market Prices
Table 102: Reimbursement Categories of Medicines in Norway
Table 103: Average Retail Coinsurance Rates by Tier, (%)
Table 104: Global Generics Industry Forecast (in USD Billion), 2016-2021
Table 105: Global Generics Industry Forecast by Volume & Percentage Growth (% of Pharma Volume), 2016-2021
Table 106: Key Financials of Allergan Plc (in USD Million), 2011-2015
Table 107: Key Financials of Aspen Pharmacare (in USD Million), 2011-2015
Table 108: Key Financials of Cipla Limited (in USD Million), 2011-2015
Table 109: Key Financials of Daiichi Sankyo (in USD Million), 2011-2015
Table 110: Key Financials of Lupin (in USD Million), 2011-2015
Table 111: Key Financials of PT Kalbe Farma Tbk (in USD Million), 2011-2015
Table 112: Key Financials of Sanofi SA (in USD Million), 2011-2015
Table 113: Key Financials of STADA Arzneimittel AG (in USD Million), 2011-2015
Table 114: Key Financials of Teva Pharmaceutical (in USD Million), 2011-2015
Table 115: Key Financials of Yuhan Corporation (in USD Million), 2011-2015
Table 116: Key Financials of Adcock Ingram (in USD Million), 2011-2015
Table 117: Key Financials of Aurobindo Pharma (in USD Million), 2011-2015
Table 118: Key Financials of China Grand Pharmaceutical and Healthcare (in USD Million), 2011-2015
Table 119: Key Financials of PT Indofarma (Persero) (in USD Million), 2011-2015
Table 120: Key Financials of Sawai Pharmaceutical (in USD Million), 2011-2015
Table 121: Key Financials of Sun Pharmaceutical (in USD Million), 2011-2015
